WeiSun, Wencheng Yu, Yanan Zhang, Shichao Cui </h5></div> Cancer Cell Research 2019 6(23) 659-665, published online 28 September 2019
||Cancer Cell Research, 2019, Vol.6 (23), pp.659-665
||Guoyu exquisite culture Co., Ltd
To evaluate the potential value of the plasma level ofreceptor- interacting protein kinase 3 (RIPK3), a keyprotein involved in the activation of necroptosis, as abiomarker for the differential diagnosis of lung cancer inpatients with lung lesions detected by chest computedtomography. The subjects of this study were divided into 3groups: lung cancer (n = 30), benign disease (n = 13), andhealthy controls (n = 33). The measurement of plasma RIPK3was performed by enzyme-linked immunosorbent assay. Theplasma RIPK3 level in patients with lung cancer (1467.4 ±347.4 pg/ml) was significantly higher than that in patientswith benign disease (1219.8 ± 156.4 pg/ml) and healthycontrols (746.2 ± 255.3 pg/ml). Besides, plasma RIPK3 levelsthat were greater than 970.06 pg/ml provided 96.7%sensitivity and... 84.8% specificity for lung cancer. Ourresults show that plasma RIPK3 levels are higher in lungcancer patients. We suggest that plasma RIPK3 level could beused as an auxiliary tool for distinguishing lung cancerfrom benign lesions and healthy lungs.